Bambusa Therapeutics Inc. BBTX · SEC Filings

website

Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in dev...

Price16.94

Market Cap862.96 M

Float10.56 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Bambusa Therapeutics Completes Initial Public Offering and Adopts Amended Corporate Governance Documents

Nov 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Oct 30, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 29, 2026

S-1MEF

Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]

Oct 29, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Oct 27, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Oct 26, 2026

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Oct 9, 2026

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Sep 14, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Nov 6, 2026

SCHEDULE 13G

ATHOS KG (Filed by)

Nov 5, 2026

RA Capital Healthcare Fund LP (Reporting)

Nov 3, 2026

Salvia Investment GmbH (Reporting)

Nov 2, 2026

Jeggle Helmut Wolfgang (Reporting)

Nov 2, 2026

Xu Shanshan (Reporting)

Nov 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 30, 2026